The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 10, 2021

Filed:

Oct. 03, 2019
Applicant:

Innoblative Designs, Inc., Chicago, IL (US);

Inventors:

Robert F. Rioux, Ashland, MA (US);

Michelle Hasse, Eau Claire, MI (US);

Tyler Wanke, Chicago, IL (US);

Assignee:

Innoblative Designs, Inc., Chicago, IL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61B 18/14 (2006.01); A61B 18/00 (2006.01); A61B 5/0538 (2021.01); A61B 5/01 (2006.01); A61B 5/287 (2021.01);
U.S. Cl.
CPC ...
A61B 18/1492 (2013.01); A61B 18/148 (2013.01); A61B 5/01 (2013.01); A61B 5/0538 (2013.01); A61B 5/287 (2021.01); A61B 18/14 (2013.01); A61B 2018/00005 (2013.01); A61B 2018/00011 (2013.01); A61B 2018/0016 (2013.01); A61B 2018/00255 (2013.01); A61B 2018/00333 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/00904 (2013.01); A61B 2018/144 (2013.01); A61B 2018/1405 (2013.01); A61B 2018/1467 (2013.01); A61B 2018/1472 (2013.01); A61B 2218/002 (2013.01); H05K 999/99 (2013.01);
Abstract

The present invention is directed to a medical device for providing treatment to diseased tissue and cells. The medical device is configured to ablate a target tissue surface, optionally within a resection cavity, and further deliver a therapeutic that targets diseased (e.g., cancer) cells via a marker whose expression is upregulated by the ablation. The ablation directly kills diseased cells associated with the tissue surface. While some diseased cells evade direct ablation, those cells nevertheless upregulate certain cell surface markers in response to the ablation, even while other, healthy or normal cells do not upregulate expression of the marker in response to the ablation. Devices and methods disclosed herein are used to deliver a therapeutic that uses the upregulated cell surface marker to cause the death of those diseased cells.


Find Patent Forward Citations

Loading…